As shown in Table 4, therapeutic strategies for counteracting ALDH2 deficiency in DCM include ALDH2 activators, SGLT2 inhibitors, antioxidants, and anti-inflammatory agents. This evidence concerns the gene SLC5A2 and familial dilated cardiomyopathy.